FDA Approves Extended Release Version of Lyrica

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

Lyrica is a common anti-epileptic used to treat muscle pain, fibromyalgia, and seizures. On October 12th, the FDA approved a new extended release version of LyricaLyrica CR.

What is Lyrica CR prescribed for?

Lyrica CR is for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), and postherpetic neuralgia (PHN).

What does CR mean?

The CR means this is an extended release formulation (aka controlled release). This means that a drug dissolves over time and is released slower into the bloodstream.

Advantages of extended release tablets include better control of pain, increased tolerability, and the convenience of only taking the medication once daily. The benefit of Lyrica CR is that you will not need to take the medication multiple times a day.

What strengths will Lyrica CR be available in?

Lyrica CR will be available in strengths of 82.5 mg, 165 mg, and 330 mg. The manufacturer, Pfizer, has not listed an anticipated launch date for Lyrica CR, but we will keep you posted! 

What are the common side effects of Lyrica CR?

Common side effects include dizziness, tiredness, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth and weight gain. Be sure to speak with your doctor if you experience any of these symptoms for a prolonged period of time.

Does Lyrica have a generic?

As of November 2017, there is no generic available for Lyrica. However, it may become available as generic pregabalin as soon as December 2018.

For more information on the release of Lyrica CR, see the press release from Pfizer here.

Put drug prices & coupons in your pocket!
We'll text you a link to download our free Android or iPhone app
Get GoodRx Mobile App

Drugs featured in this story

Filed under